Evotec’s Post

The next CCO #PaperOfTheWeek is brought to us by Erdi Kara, Aminur Rahman, PhD, Eugenio Aulisa, and Souparno Ghosh. Their paper, "Tumor ablation due to inhomogeneous anisotropic diffusion in generic three-dimensional topologies", presents a 3D model of anisotropic diffusion in tumors to simulate drug concentration heat maps, apoptosis hotspots, and dose-response curves. Consider checking it out: https://lnkd.in/g7iVydTD.

Preclinical studies of INM-089 demonstrated significant functional and pathological improvements in an age-related macular degeneration (#AMD) disease study model. Studies showed INM-089 provides neuroprotection of photoreceptors, reduces extracellular autofluorescent (AF) deposits, preserves retinal function and improves the integrity of the retinal pigment epithelium (RPE) and thickness of the outer nuclear layer (ONL) of the retina. Based on widely accepted ocular research, the thickness of the #ONL is strongly correlated with photoreceptor preservation and visual acuity. More about INM-089: https://ow.ly/IHH050TBOYs $INM #dryAMD #preclinical #study

I am always intrigued by the insights provided by our colleagues in Biophysics to our drug design process. If you are interested in the driving forces of molecular recognition, or new to the area and wish to know more, then please join Florian for his fascinating Webinar

Radiopharmaceuticals: Igniting the Molecular Gala 🎇✨ Radiopharmaceuticals stand out as the luminaries 🌟 of the molecular gala, casting their radiant glow through emissions detected by our specialized cameras 📸. This extraordinary feature enables us to discern whether the body's molecular festivities 🎉 are in full bloom or if an unwelcome intruder, like a tumor, is attempting to dim the celebrations 🚫. These standout molecules don't just shed light; they revolutionize 🔄 our insight into the body's intricate dynamics, steering us towards pinpoint diagnoses and therapies targeted with precision 🎯. Step into the realm of scientific revelry 🥳 where radiopharmaceuticals choreograph the rhythm, ensuring the party's vibrance is safeguarded and thriving. #molim #radiopharmaceuticals #dosimetry

If you are in the southwest and building a flow panel, send me a message! #Flow #flowcytometry #cyto #starbrights #antibodies #spectral #research #immunology #cellbiology #science

What are the benefits of using Surface Plasmon Resonance (SPR)? The data generated using SPR can be highly valuable at any stage of the drug discovery pipeline. At BioAscent we use it both as a standalone technique for answering discreet project questions and as a key component to enable success in fully integrated drug discovery projects. Find out more about our SPR and biophysics expertise here: https://bit.ly/46Kde9j #IntegratedDrugDiscovery #DiscoveryBiology #Biosciences #AssayDevelopment #SPRassays

Delve into biophysical screening in early drug discovery in our upcoming webinar, the third installment of our hit identification series: Molecular Interactions Matter - Biophysical Screening for Early Drug Discovery Join us as Dr. Florian Krieger, VP Biophysics, presents Evotec’s most recent developments in biophysical screening approaches during early drug discovery stages, including an introduction to Evotec’s library sets suitable for biophysical screening. Florian will further discuss case studies covering lead-like screening, fragment-based approaches, and covalent hit identification. Date: 9 July 2024 Time: The webinar is available in multiple time zones. Please select the option that best meets your needs. 9am CET | 8am BST | 3am EST | 12am PST | 4pm JST 5pm CET | 4pm BST | 11am EST | 8am PST | 12am JST Don't miss out! Secure your spot now: https://hubs.ly/Q02Bkd5F0 #researchneverstops #Evotec #HitIdentification #BiophysicalScreening #MolecularInteractions

In case you missed the live session, here is the link to the on-demand version of our HitID and Biophysics webinar!

Satellos Bioscience Inc. has shared preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy (FSHD), which is promising for their initiation the first-in-human clinical trial of this compound in #Duchenne #musculardystrophy later this year: https://bit.ly/3uywTMv.

We are back with a new episode of the Hit ID webinar series!! Don't miss the next chapter and explore molecular interactions with Dr. Florian Krieger! #researchneverstops #Evotec #HitIdentification #BiophysicalScreening #MolecularInteractions